We are live on ! Find out more
NUS icon

Nu Skin

202 hedge funds and large institutions have $443M invested in Nu Skin in 2024 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 77 increasing their positions, 62 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

24% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 62

14% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 36

4.53% more ownership

Funds ownership: 80.03%84.56% (+4.5%)

2% more funds holding

Funds holding: 198202 (+4)

19% less capital invested

Capital invested by funds: $548M → $443M (-$105M)

87% less call options, than puts

Call options by funds: $352K | Put options by funds: $2.75M

Holders
202
Holders Change
+4
Holders Change %
+2.02%
% of All Funds
2.92%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
41
Increased
77
Reduced
62
Closed
36
Calls
$352K
Puts
$2.75M
Net Calls
-$2.4M
Net Calls Change
-$1.31M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$85.6M -$2.83M -223,396 -3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$69M +$715K +56,383 +0.9%
Pacer Advisors
3
Pacer Advisors
Pennsylvania
$25.2M +$30.3M +2,393,768 New
State Street
4
State Street
Massachusetts
$20.8M -$783K -61,765 -3%
Renaissance Technologies
5
Renaissance Technologies
New York
$18.5M -$530K -41,800 -2%
Federated Hermes
6
Federated Hermes
Pennsylvania
$14M +$8.85M +698,722 +112%
D.E. Shaw & Co
7
D.E. Shaw & Co
New York
$13.8M +$4.22M +332,860 +34%
Charles Schwab
8
Charles Schwab
California
$13.1M -$1.87M -147,217 -11%
Morgan Stanley
9
Morgan Stanley
New York
$13M +$762K +60,143 +5%
Geode Capital Management
10
Geode Capital Management
Massachusetts
$11.8M +$465K +36,687 +3%
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$9.92M -$1.65M -130,164 -12%
Bank of New York Mellon
12
Bank of New York Mellon
New York
$9.5M +$557K +43,935 +5%
ACB
13
Aristotle Capital Boston
Massachusetts
$8.1M -$546K -43,113 -5%
American Century Companies
14
American Century Companies
Missouri
$5.96M +$1.24M +98,243 +21%
Invesco
15
Invesco
Georgia
$5.73M +$410K +32,332 +6%
Millennium Management
16
Millennium Management
New York
$5.63M +$3.4M +267,965 +101%
Goldman Sachs
17
Goldman Sachs
New York
$5.61M +$4.16M +328,523 +161%
Northern Trust
18
Northern Trust
Illinois
$5.4M -$264K -20,833 -4%
Norges Bank
19
Norges Bank
Norway
$5.34M -$556K -43,848 -8%
ProShare Advisors
20
ProShare Advisors
Maryland
$5.33M -$1.17M -92,020 -15%
Hotchkis & Wiley Capital Management
21
Hotchkis & Wiley Capital Management
California
$4.98M +$440K +34,750 +8%
Two Sigma Advisers
22
Two Sigma Advisers
New York
$4.07M -$791K -62,422 -14%
PGCM
23
Prescott Group Capital Management
Oklahoma
$3.65M +$3.88M +306,311 +758%
Jacobs Levy Equity Management
24
Jacobs Levy Equity Management
New Jersey
$3.35M +$434K +34,233 +12%
Two Sigma Investments
25
Two Sigma Investments
New York
$2.94M +$328K +25,854 +10%

NUS Hedge Fund Activity: Q2 2024 in Review

202 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Nu Skin (NUS) for Q2 2024, worth a combined $443M — down 19% from $548M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new NUS positions and 36 closed out — a net gain of 5 holders — while 77 added to existing stakes and 62 trimmed.

The largest buyer was Pacer Advisors, opening a new position worth an estimated $30.3M. The largest seller was Allianz Asset Management, cutting an estimated $4.05M.

  • 202 institutional investors held Nu Skin (NUS) as of Q2 2024, up from 198 in Q1 2024.
  • Funds reported $443M of Nu Skin stock for Q2 2024, down 19% quarter-over-quarter.
  • 41 funds opened new Nu Skin positions in Q2 2024 and 36 closed out, a net change of +5 holders.
  • The largest Nu Skin buyer in Q2 2024 was Pacer Advisors, an estimated $30.3M added.
  • The largest Nu Skin seller in Q2 2024 was Allianz Asset Management, an estimated $4.05M sold.

Based on aggregated 13F filings for Q2 2024.